UroGen Pharma Ltd.
URGN
$9.87
-$0.24-2.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -44.19% | -8.20% | -38.39% | -6.86% | 9.88% |
| Total Depreciation and Amortization | -27.83% | -35.90% | -38.98% | -19.31% | -5.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 60.41% | -6.73% | 29.39% | -20.03% | 23.06% |
| Change in Net Operating Assets | 105.06% | -515.52% | 263.14% | -281.74% | 296.75% |
| Cash from Operations | -4.79% | -59.92% | -17.14% | -22.97% | 40.25% |
| Capital Expenditure | -105.36% | 4.00% | -460.00% | -- | -330.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 638.06% | -21,388.22% | 223.48% | 114.81% | -148.82% |
| Cash from Investing | 634.39% | -26,720.95% | 222.53% | 115.60% | -149.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 77.50% | -77.56% | 56,993.71% | 8,045.60% | -89.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Financing | 77.50% | -65.88% | 70,029.37% | 8,045.60% | -99.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 293.72% | -195.59% | 639.49% | 293.15% | -190.93% |